<DOC>
	<DOCNO>NCT00988507</DOCNO>
	<brief_summary>Primary objective : To assess Day 28 efficacy define percentage patient parasitic recrudescence , 3 treatment group - 3 dose level ferroquine associate artesunate - 3-day treatment . Secondary objective : - To assess efficacy ferroquine one dose level alone 3-day treatment . - To assess clinical safety 4 treatment group - 3 dose level ferroquine associate artesunate one dose level ferroquine alone . - To assess pharmacokinetics parameter ferroquine metabolite along sparse sampling schedule .</brief_summary>
	<brief_title>Dose Ranging Study Ferroquine With Artesunate African Adults Children With Uncomplicated Plasmodium Falciparum Malaria</brief_title>
	<detailed_description>The overall study duration 64 day , consist screen period ( less equal 1 day ) , 3-day treatment period patient hospitalize maximum 60 hour , follow-up period 61 day .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>3 cohort enrol sequence data interim review Data Monitoring Committee ( DMC ) cohort 12 cohort 23 Cohort 1 : Adults &gt; 50 kg Adolescents &gt; 30 kg age &gt; = 14 year Cohort 2 : Children body weight [ 30 kg 15 kg [ Cohort 3 : Children body weight [ 15 kg10 kg ] Age relate Body Mass Index ( BMI ) &gt; = 5 th percentile . Presence body temperature &gt; = 37.5Â°C history fever last 24 hour . Monoinfection Plasmodium falciparum parasitemia 1,000/microL 200,000/microL . Signed Informed Consent Form patient ( patient &gt; = age define majority ) parent legal guardian minor patient ( &lt; 18 year age &lt; age locally define majority ) . In addition , participant capacity write sign Assent Form . Patients capacity write Assent Form read . In case , impartial witness certify document read child . Presence HBs antigen antiHCV antibody Laboratory parameter clinical significant abnormality and/or reach critical value : Hemoglobin ( &lt; 7g/dl ) , hematocrit , red blood cell count , white blood cell , reticulocytes , platelet , glucose , creatinine , aspartate transferase ( AST ) , alanine transferase ( ALT &gt; 3 ULN ) , alkaline phosphatase , total bilirubine &gt; 1.5 ULN . History presence clinically significant disease symptom might confound interpretation safety efficacy information . Splenectomized patient . Presence criterion complicate malaria Patients unable drink Breastfeeding patient . Permanent vomiting . Female participant child bear potential willing use effective contraceptive ( ) method ( ) duration study ( e.g . implant , oral contraceptive , intrauterine device double barrier method ) . The need efficient method remind patient patient 's legal guardian ( ) investigator . Previous treatment within 5 time elimination halflife within last 14 day , whichever long : antimalaria agent i.e. , quinine , chloroquine , amodiaquine , mefloquine , halofantrine , sufladoxinepyrimethamine , doxycyclinepyrimethamine , primaquine , artemether , atovaquone , proguanil , lumefantrine , investigational drug 2D6 main substrate Past concomitant participation study antimalaria vaccine . Measles vaccine injection within last 15 day .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>